Business Description
BioPharma Credit PLC
ISIN : GB00BDGKMY29
Description
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.99 | |||||
Debt-to-EBITDA | N/A |
N/A
|
N/A
| |||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 7/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.9 | |||||
3-Year EPS without NRI Growth Rate | -5.2 | |||||
3-Year FCF Growth Rate | -16 | |||||
3-Year Book Growth Rate | 0.2 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.59 | |||||
9-Day RSI | 55.19 | |||||
14-Day RSI | 54.89 | |||||
3-1 Month Momentum % | 2.13 | |||||
6-1 Month Momentum % | 4.8 | |||||
12-1 Month Momentum % | 8.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 7.29 | |||||
Dividend Payout Ratio | 0.62 | |||||
Forward Dividend Yield % | 7.29 | |||||
5-Year Yield-on-Cost % | 7.34 | |||||
3-Year Average Share Buyback Ratio | 5.1 | |||||
Shareholder Yield % | 12.03 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Net Margin % | 98.36 | |||||
FCF Margin % | 68.98 | |||||
OCF Margin % | 68.98 | |||||
ROE % | 11.19 | |||||
ROA % | 11.05 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 8.42 | |||||
PE Ratio without NRI | 8.42 | |||||
PEG Ratio | 28.07 | |||||
PS Ratio | 8.27 | |||||
PB Ratio | 0.94 | |||||
Price-to-Tangible-Book | 0.94 | |||||
Price-to-Free-Cash-Flow | 12.01 | |||||
Price-to-Operating-Cash-Flow | 12.01 | |||||
EV-to-Revenue | 8.11 | |||||
EV-to-FCF | 11.71 | |||||
Price-to-GF-Value | 0.99 | |||||
Price-to-Projected-FCF | 0.52 | |||||
Price-to-Graham-Number | 0.59 | |||||
FCF Yield % | 8.41 | |||||
Forward Rate of Return (Yacktman) % | 9.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioPharma Credit PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 132.055 | ||
| EPS (TTM) ($) | 0.114 | ||
| Beta | -0.2895 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.24 | ||
| Volatility % | 8.43 | ||
| 14-Day RSI | 54.89 | ||
| 14-Day ATR ($) | 0.011528 | ||
| 20-Day SMA ($) | 0.9549 | ||
| 12-1 Month Momentum % | 8.6 | ||
| 52-Week Range ($) | 0.856 - 1 | ||
| Shares Outstanding (Mil) | 1,122.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioPharma Credit PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioPharma Credit PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-22 13:00 | In 83 days | ||
| Second quarter earnings results for 2026 | 2026-09-22 | In 82 days | ||
| USD 0.017500 Cash Dividend | 2026-07-02 | 0.95 (-0.83%) | ||
| General meeting for 2026 | 2026-06-17 12:00 | 0.94 (-0.42%) | ||
| USD 0.017500 Cash Dividend | 2026-04-30 | 0.94 (+0.43%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 14:00 | 0.93 (-1.06%) | ||
| Annual report for 2025 | 2026-03-24 | 0.93 (-1.06%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 0.93 (-1.06%) | ||
| USD 0.014460 Cash Dividend | 2026-02-19 | 0.97 (+0.21%) | ||
| USD 0.017500 Cash Dividend | 2026-02-19 | 0.97 (+0.21%) |
Show
Entries
BioPharma Credit PLC Frequently Asked Questions
What is BioPharma Credit PLC(LSE:BPCR)'s stock price today?
The current price of LSE:BPCR is $0.96. The 52 week high of LSE:BPCR is $1.00 and 52 week low is $0.86.
When is next earnings date of BioPharma Credit PLC(LSE:BPCR)?
The next earnings date of BioPharma Credit PLC(LSE:BPCR) is 2026-09-22 Est..
Does BioPharma Credit PLC(LSE:BPCR) pay dividends? If so, how much?
The Dividend Yield %  of BioPharma Credit PLC(LSE:BPCR) is 7.29% (As of Today), Highest Dividend Payout Ratio of BioPharma Credit PLC(LSE:BPCR) was 1.13. The lowest was 0.52. And the median was 0.8. The  Forward Dividend Yield % of BioPharma Credit PLC(LSE:BPCR) is 7.29%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on BioPharma Credit PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers